A. John Iafrate

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Oxidized protein states define metastatic fitness in lung cancer

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-06-11

• Clinical validation of an HPV whole-genome sequencing assay for MRD detection in patients with HPV+ head and neck cancer treated with surgery

  Science Translational Medicine · 2026-06-10

• Weak supervision of H&E slides reveals systems-level biology and functional states that govern therapeutic resistance

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-05-08

• Abstract 5865: Developing COUPLrs, dual-warhead cysteine-reactive compounds, to target oncoproteins through interaction modulation and degradation

  Cancer Research · 2026-04-03

• Abstract 4299: STING pathway activation reveals feedback inhibition potentially limiting immunostimulatory response in adenoid cystic carcinoma

  Cancer Research · 2026-04-03

• Supplementary Table S2 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

  2026-04-01

• Data from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

  2026-04-01

• Supplementary Figure S2 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

  2026-04-01

• Supplementary Table S3 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

  2026-04-01

• Supplementary Table S5 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

  2026-04-01

• Supplementary Figure S5 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

  2026-04-01

• Supplementary Figure S1 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

  2026-04-01

• Supplementary Figure S4 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

  2026-04-01

• Supplementary Figure S3 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

  2026-04-01

• Supplementary Table S4 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

  2026-04-01

• Supplementary Table S1 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

  2026-04-01

• Supplementary Figure S6 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

  2026-04-01

• Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

  Clinical Cancer Research · 2026-01-20 · 1 citations

• Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial

  Nature Medicine · 2026-01-16 · 1 citations

• The PIK3CA/AKT pathway drives therapy resistance in rhabdomyosarcoma

  Nature Communications · 2025-12-10